CRL has a higher market value than 85.6% of US stocks; more precisely, its current market capitalization is $13,989,616,136.
With a one year PEG ratio of 177.64, Charles River Laboratories International Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 81.81% of US stocks.
The price/operating cash flow metric for Charles River Laboratories International Inc is higher than 77.9% of stocks in our set with a positive cash flow.
Stocks that are quantitatively similar to CRL, based on their financial statements, market capitalization, and price volatility, are PRAH, BR, TTEK, RXN, and FOXA.
Charles River Laboratories International, Inc. (CRL) Company Bio
Charles River Laboratories provides products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. The company was founded in 1947 and is based in Wilmington, Massachusetts.
CRL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Charles River Laboratories International Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Charles River Laboratories International Inc ranked in the 37th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Charles River Laboratories International Inc, consider:
87% of the company's capital comes from equity, which is greater than 66.47% of stocks in our cash flow based forecasting set.
The weighted average cost of capital for the company is 9. This value is greater than just 23.35% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Charles River Laboratories International Inc? See MMSI, MGLN, PKI, ITGR, and IART.
Ariel Investments, a minority-owned investment company that focuses in small and mid-capitalized US based stocks, published its third-quarter 2020 Investor Letter – a copy of which can be downloaded here. A positive return of 4.56% was recorded by the fund for the 3rd Quarter of 2020, ahead of its Russell 2500 Value benchmark that returned 3.54%. […]